Literature DB >> 25120078

Use of ultrasound in the insertion of a vascular closure device: a comparative retrospective study with the standard blind technique.

Pierleone Lucatelli1, Alessandro Cannavale, Carlo Cirelli, Alessandro d'Adamo, Filippo Maria Salvatori, Fabrizio Fanelli.   

Abstract

PURPOSE: To evaluate whether ultrasound (US) assistance can decrease the rate of complications related to the use of vascular closure devices (VCDs).
MATERIALS AND METHODS: A retrospective comparative study was done on 150 consecutive patients who had a VCD inserted under US guidance after retrograde common-femoral-artery (CFA) puncture. This group was compared to a historical control group of 150 consecutive patients who had the same VCDs inserted with the standard blind technique. After the procedures, patients were placed at bedrest for at least 6 h. Technical success, defined as correct deployment without adjunctive manual compression, blood count and US evaluation of the arterial puncture site was done at 24 h and at 3 months. Differences in terms of efficacy and safety were statistically evaluated using US guidance as a predictor for a lower complication rate.
RESULTS: Technical success was achieved in 147/150 patients (98 %) in the study group vs. 141/150 cases (94 %) of the control group (p = 0.038). In three cases (2 %) adjunctive manual compression (≤5 min) was required. One pseudoaneurysm (0.65 %) occurred after 24 h, solved with manual compression. Six minor complications (4 %)--haematoma (n = 5; 3.35 %), recurrent wound bleeding (n = 1; 0.65 %)--were reported. In the control group four (2.65 %) major complications occurred: CFA occlusion managed with surgical bypass, CFA dissection solved by surgical bypass, two pseudoaneurysms solved with manual compression. Thirteen (8.65 %) minor complications were observed with haematoma (n = 10; 6.65 %), and recurrent wound bleeding (n = 3; 2.0 %). The comparative analysis of the total complication rate and major complication rate between the study group and the control group was statistically significant (p = 0.016 and p = 0.049, respectively). A 24-h evaluation showed a triphasic flow within the CFA in 150/150 patients (100 %) of the study group and in 146/150 cases (97.35 %) of the control group.
CONCLUSION: VCD inserted under US guidance increases the success rate reducing the number of complications.

Entities:  

Mesh:

Year:  2014        PMID: 25120078     DOI: 10.1007/s11547-014-0439-3

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  23 in total

Review 1.  An overview of vascular closure devices: what every radiologist should know.

Authors:  L Q Hon; A Ganeshan; S M Thomas; D Warakaulle; J Jagdish; R Uberoi
Journal:  Eur J Radiol       Date:  2008-11-28       Impact factor: 3.528

2.  Posterior wall capture and resultant common femoral occlusion complicating StarClose access closure.

Authors:  Patrick A Stone; John E Campbell; Karinna H Andrews; Mark C Bates
Journal:  J Vasc Surg       Date:  2008-08       Impact factor: 4.268

3.  Fluoroscopy vs. traditional guided femoral arterial access and the use of closure devices: a randomized controlled trial.

Authors:  Mazen S Abu-Fadel; Jeffrey M Sparling; Soni J Zacharias; Christopher E Aston; Jorge F Saucedo; Eliot Schechter; Thomas A Hennebry
Journal:  Catheter Cardiovasc Interv       Date:  2009-10-01       Impact factor: 2.692

4.  A comparative evaluation of arterial blood flow and the healing response after femoral artery closure using angio-seal STS Plus and StarClose in a porcine model.

Authors:  Pramod Sanghi; Renu Virmani; Dat Do; John Erikson; James Elliott; Mehmet Cilingiroglu; Holly Matthews; Masood Kazi; Robert Ricker; Steven R Bailey
Journal:  J Interv Cardiol       Date:  2008-06-28       Impact factor: 2.279

5.  Influence of use of a vascular closure device on incidence and surgical management of access site complications after percutaneous interventions.

Authors:  J Klocker; A Gratl; A Chemelli; N Moes; G Goebel; G Fraedrich
Journal:  Eur J Vasc Endovasc Surg       Date:  2011-04-16       Impact factor: 7.069

6.  Comparison of costs and safety of a suture-mediated closure device with conventional manual compression after coronary artery interventions.

Authors:  Hans Rickli; Martin Unterweger; Gabor Sütsch; Hans Peter Brunner-La Rocca; Markus Sagmeister; Peter Ammann; Franz W Amann
Journal:  Catheter Cardiovasc Interv       Date:  2002-11       Impact factor: 2.692

7.  The StarClose vascular closure device in antegrade and retrograde punctures: a single-center experience.

Authors:  Albert Ho Yuen Chiu; Simon Richard Coles; Jonathan Tibballs; Sanjay Nadkarni
Journal:  J Endovasc Ther       Date:  2010-02       Impact factor: 3.487

8.  Laceration of the common femoral artery following deployment of the starclose vascular closure system.

Authors:  Michael Gonsalves; Miles Walkden; Anna Maria Belli
Journal:  Cardiovasc Intervent Radiol       Date:  2008-05-28       Impact factor: 2.740

9.  The safety and efficacy of angioseal in therapeutic endovascular interventions.

Authors:  M Aksoy; J-P Becquemin; P Desgranges; E Allaire; H Kobeiter
Journal:  Eur J Vasc Endovasc Surg       Date:  2006-02-14       Impact factor: 7.069

10.  CIRSE vascular closure device registry.

Authors:  Jim A Reekers; Stefan Müller-Hülsbeck; Martin Libicher; Eli Atar; Jens Trentmann; Pierre Goffette; Jan Borggrefe; Kamil Zeleňák; Pieter Hooijboer; Anna-Maria Belli
Journal:  Cardiovasc Intervent Radiol       Date:  2010-10-28       Impact factor: 2.740

View more
  2 in total

1.  Nitinol clip distal migration and resultant popliteo-tibial artery occlusion complicating access closure by the StarClose SE vascular closure system.

Authors:  Dae Han Choi; Myeong Jin Kim; Chan Jong Yoo; Cheol Wan Park
Journal:  BMJ Case Rep       Date:  2016-03-30

2.  Acute lower limb ischemia following Angio-Seal deployment after transfemoral percutaneous coronary intervention.

Authors:  Michał Walczewski; Adam Rdzanek; Ewa Pędzich-Placha; Janusz Kochman
Journal:  Kardiochir Torakochirurgia Pol       Date:  2019-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.